1,721,001 research outputs found
Efficacy of Adalimumab as first-line “top-down” therapy in pediatric Crohn's Disease: 12 months of follow-up
No full textObjectives and Study: Anti-tumour necrosis factor (TNF) agents are highly efficient in inducing and
maintaining remission in pediatric Crohn's disease (CD). The question is who is the right patient and
when is the right moment to introduce anti-TNF medication. Recent ECCO-ESPGHAN guidelines
indicate a clear place of anti-TNF biologics in patients with positive predictors of poor outcome. The
aim of our study was to evaluate the efficacy of adalimumab (ADA) as first-line therapy by comparing
two НiffОrОnt stratОgiОsŚ χDχ “top Нown” in immunomoНulator anН anti-TNF naïve CD patients versus
a “stОp up” stratОgy in patiОnts rОМОiving immunosupprОssivО agОnts (thiopurinО anН/or infliximabΨ
before ADA.
Method: Patients followed for CD at Necker hospital that started their ADA therapy between 2005 and
2017 were retrospectively reviewed. The beginning of the study (M0) was the date of first ADA
injection. Enrolled patients were divided into 2 groups according to the treatment strategy. Group A
was composed of patients naïve of immunosuppressors and anti TNF agents who started early ADA
aftОr inНuМtion of rОmission, rОsulting in a “top Нown” stratОgy whilО group ψ was МomposОН by
patiОnts who startОН χDχ aftОr a morО МlassiМal stratОgy (iО “stОp up” stratОgy using
immunosuppressive agents then infliximab). For each patient were collected data at M0, M3, M6, M9
and M12 regarding the disease activity score (wPCDAI), auxological parameters, biological
parameters (CRP, ESR, Albumin, ADA trough levels and antibodies anti-ADA).
Results: 83 patients (43 boys) were enrolled in the study, 43,3% (n=36) in group A and 56,6% (n=47)
in group B. Mean age at the start of ADA was 13.6 ± 2.6 years. At inclusion the 2 groups were
comparable with a mean wPCDAi of 40.75 ± 14,8 in group A versus 45.6 ± 15,5 in group B.
At 6 months, the 2 groups were in clinical remission with a median wPCDAI of 0 (0-12.5 IQR) in group
A (n = 30) versus 0 (0-7.5 IQR) in group B (n=38) (p: 0.509). CRP level decreased from 15.5 (4.7-35.8
IQR) to 1.1 (0.5-5.6 IQR) in group A vs 17.1 (6.5-37.7 IQR) to 4,8 (0.7-6.1 IQR) in group B (p: 0.945 e
p: 0.086). For the subgroup of patients who reached the 1 year follow up, there were no significant
differences regarding the mean wPCDAI, CRP, ESR and serum allbumin between the 2 groups.
Conclusion: ThО prОsОnt stuНy НОmonstratОs that thО “top Нown” stratОgy using Оarly χDχ
monotherapy in disease course is as effective as a step-up strategy. Moreover, ADA monotherapy is
as effective as combotherapy in maintaining clinical and biological remission at 1 year of follow-up in
paediatric CD patients. Those results are very important to identify the best strategy in pediatric CD
patients, where safety concerns are major
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Use of oral vancomycin in children with autoimmune liver disease: A single centre experience
No full text
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
